Cyrus has broad and unique experience in cytokines
Experience in cytokine engineering & modeling
• 11 different cytokines
• With 7 different companies including Selecta’s ImmTOR-IL program
Broad accomplishment in cytokine engineering
• Modification of receptor subtype
• Modification of BP binding
• Creation of AI designed de novo mimic proteins
• Creation and modification of fusion proteins
• Stabilization & improved affinity for improved activity
Cyrus is collaborating with other firms on multiple cytokine engineering projects and pursuing in house next-gen cytokines
• Next-Gen IL22 for autoimmune, tissue protection, and metabolic indications
• Next-Gen IL15 with high potency and extended therapeutic index for oncology
Origin
Because the system is bacterial in origin, a proportion of treated patients may mount an immune response against the enzyme — pre existing adaptive immunity was very clearly shown in 2019 by Charlesworth et al in Nature Medicine https://www.nature.com/articles/s41591-018-0326-x. At a minimum this response could sharply reduce the utility of this system, requiring pre-screening of prospective recipients or prophylactic immune suppression. Cyrus and The Broad Institute in Cambridge, MA are collaborating on the deimmunization of CRISPR systems with the goal of eliminating the risk of such immune responses.
INTERESTED IN
PARTNERING WITH US ON
PROTEIN THERAPEUTICS?